Mastoparan

General Information


DRACP ID  DRACP02657

Peptide Name   Mastoparan

Sequence  INLKALAALAKKIL

Sequence Length  14

UniProt ID  Not available

PubChem CID  Not available

Origin  Vespula lewisii

Type  Synthetic peptide

Classification

  

Active ACP Cell-penetrating peptides



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
HeLa Human papillomavirus-related endocervical adenocarcinoma Carcinoma IC50=13 µM MTT assay 20 h 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antimicrobial



Structure Information


PDB ID  Not available

Predicted Structure  DRACP02657

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Tetramethylguanidine

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C70H130N18O16

Absent amino acids  CDEFGHMPQRSTVWY

Common amino acids  AL

Mass  171201

Pl  11.1

Basic residues  3

Acidic residues  0

Hydrophobic residues  10

Net charge  3

Boman Index  1347

Hydrophobicity  115.71

Aliphatic Index  195.71

Half Life 
  Mammalian: 20 hour
  Yeast: 30 min
  E.coli: >10 hour

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  1

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 26114809

Title  Sequence-activity relationship, and mechanism of action of mastoparan analogues against extended-drug resistant Acinetobacter baumannii

Doi 10.1016/j.ejmech.2015.06.016

Year  2015

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.